Sensus (SRTS) insider buys 1,000 shares at $4.26
Sensus Healthcare (SRTS) officer and director Michael Sardano reported open‑market purchases on November 11, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Sensus Healthcare (SRTS) officer and director Michael Sardano reported open‑market purchases on November 11, 2025.
He acquired 1,000 shares of common stock at $4.26 held directly. Additional purchases were reported for his spouse of 766 shares at $4.27 and 234 shares at $4.24. Following these transactions, Sardano held 117,839 shares directly. He disclaims beneficial ownership of his spouse’s shares. Sardano serves as President and General Counsel and is also a Director.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 1,000 | $4.26 | $4K |
| Purchase | Common Stock | 766 | $4.27 | $3K |
| Purchase | Common Stock | 234 | $4.24 | $992.16 |
Footnotes (1)
- F1. Shares held by Mr. Sardano's spouse, as to which he disclaims beneficial ownership.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did SRTS report for Michael Sardano?
What roles does Michael Sardano hold at Sensus Healthcare (SRTS)?
What was the transaction type on the Form 4/A for SRTS?
When was the earliest transaction date reported for SRTS?
AI-generated analysis. How Rhea-AI works. Not financial advice.